Cite
HARVARD Citation
Taylor, P. et al. (2014). A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1. Annals of the rheumatic diseases. p. A31. [Online].